Tags

Type your tag names separated by a space and hit enter

Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways.
J Cell Physiol. 2018 Mar; 233(3):2502-2512.JC

Abstract

Over-production and activation of osteoclasts is a common feature of osteolytic conditions such as osteoporosis, tumor-associated osteolysis, and inflammatory bone erosion. Cyanidin Chloride, a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties, but its role in osteoclastic bone resorption and osteoporosis is not well understood. In this study, we showed that Cyanidin Chloride inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression; including ctr, ctsk, and trap. Further investigation revealed that Cyanidin Chloride inhibits RANKL-induced NF-κB activation, suppresses the degradation of IκB-α and attenuates the phosphorylation of extracellular signal-regulated kinases (ERK). In addition, Cyanidin Chloride abrogated RANKL-induced calcium oscillations, the activation of nuclear factor of activated T cells calcineurin-dependent 1 (NFATc1), and the expression of c-Fos. Further, we showed that Cyanidin Chloride protects against ovariectomy-induced bone loss in vivo. Together our findings suggest that Cyanidin Chloride is capable of inhibiting osteoclast formation, hydroxyapatite resorption and RANKL-induced signal pathways in vitro and OVX-induced bone loss in vivo, and thus might have therapeutic potential for osteolytic diseases.

Authors+Show Affiliations

Research Center for Regenerative Medicine, and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi, China. Department of Orthopaedic Surgery, the First Affiliated Hospital of Guangxi Medical University, Guangxi, China. School of Pathology and Laboratory Medicine, The University of Western Australia, Perth, Western Australia, Australia.School of Pathology and Laboratory Medicine, The University of Western Australia, Perth, Western Australia, Australia.Research Center for Regenerative Medicine, and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi, China.School of Pathology and Laboratory Medicine, The University of Western Australia, Perth, Western Australia, Australia.Research Center for Regenerative Medicine, and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi, China. Department of Orthopaedic Surgery, the First Affiliated Hospital of Guangxi Medical University, Guangxi, China.Research Center for Regenerative Medicine, and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi, China. Department of Orthopaedic Surgery, the First Affiliated Hospital of Guangxi Medical University, Guangxi, China.Jiangsu Key Laboratory for Molecular and Medical Biotechnology and College of Life Sciences, Nanjing Normal University, Nanjing, China.Research Center for Regenerative Medicine, and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi, China.Research Center for Regenerative Medicine, and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi, China.School of Surgery, The University of Western Australia, Perth, Western Australia, Australia.Research Center for Regenerative Medicine, and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi, China. Department of Orthopaedic Surgery, the First Affiliated Hospital of Guangxi Medical University, Guangxi, China. Guangxi Collaborative Innovation Center for Biomedicine, Guangxi Medical University, Guangxi, China.Research Center for Regenerative Medicine, and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi, China. School of Pathology and Laboratory Medicine, The University of Western Australia, Perth, Western Australia, Australia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28771720

Citation

Cheng, Jianwen, et al. "Cyanidin Chloride Inhibits Ovariectomy-induced Osteoporosis By Suppressing RANKL-mediated Osteoclastogenesis and Associated Signaling Pathways." Journal of Cellular Physiology, vol. 233, no. 3, 2018, pp. 2502-2512.
Cheng J, Zhou L, Liu Q, et al. Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways. J Cell Physiol. 2018;233(3):2502-2512.
Cheng, J., Zhou, L., Liu, Q., Tickner, J., Tan, Z., Li, X., Liu, M., Lin, X., Wang, T., Pavlos, N. J., Zhao, J., & Xu, J. (2018). Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways. Journal of Cellular Physiology, 233(3), 2502-2512. https://doi.org/10.1002/jcp.26126
Cheng J, et al. Cyanidin Chloride Inhibits Ovariectomy-induced Osteoporosis By Suppressing RANKL-mediated Osteoclastogenesis and Associated Signaling Pathways. J Cell Physiol. 2018;233(3):2502-2512. PubMed PMID: 28771720.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways. AU - Cheng,Jianwen, AU - Zhou,Lin, AU - Liu,Qian, AU - Tickner,Jennifer, AU - Tan,Zhen, AU - Li,Xiaofeng, AU - Liu,Mei, AU - Lin,Xixi, AU - Wang,Tao, AU - Pavlos,Nathan J, AU - Zhao,Jinmin, AU - Xu,Jiake, Y1 - 2017/09/07/ PY - 2016/10/31/received PY - 2017/08/01/accepted PY - 2017/8/5/pubmed PY - 2017/12/13/medline PY - 2017/8/4/entrez KW - Cyanidin Chloride KW - RANKL KW - bone resorption KW - osteoclast KW - osteolysis SP - 2502 EP - 2512 JF - Journal of cellular physiology JO - J Cell Physiol VL - 233 IS - 3 N2 - Over-production and activation of osteoclasts is a common feature of osteolytic conditions such as osteoporosis, tumor-associated osteolysis, and inflammatory bone erosion. Cyanidin Chloride, a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties, but its role in osteoclastic bone resorption and osteoporosis is not well understood. In this study, we showed that Cyanidin Chloride inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression; including ctr, ctsk, and trap. Further investigation revealed that Cyanidin Chloride inhibits RANKL-induced NF-κB activation, suppresses the degradation of IκB-α and attenuates the phosphorylation of extracellular signal-regulated kinases (ERK). In addition, Cyanidin Chloride abrogated RANKL-induced calcium oscillations, the activation of nuclear factor of activated T cells calcineurin-dependent 1 (NFATc1), and the expression of c-Fos. Further, we showed that Cyanidin Chloride protects against ovariectomy-induced bone loss in vivo. Together our findings suggest that Cyanidin Chloride is capable of inhibiting osteoclast formation, hydroxyapatite resorption and RANKL-induced signal pathways in vitro and OVX-induced bone loss in vivo, and thus might have therapeutic potential for osteolytic diseases. SN - 1097-4652 UR - https://www.unboundmedicine.com/medline/citation/28771720/Cyanidin_Chloride_inhibits_ovariectomy_induced_osteoporosis_by_suppressing_RANKL_mediated_osteoclastogenesis_and_associated_signaling_pathways_ L2 - https://doi.org/10.1002/jcp.26126 DB - PRIME DP - Unbound Medicine ER -